Cargando…

Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study

BACKGROUND: This study investigated medication adherence in kidney transplant patients (KTPs) converted from immediate-release tacrolimus (IR-T) to prolonged-release tacrolimus (PR-T)-based immunosuppression in routine practice. METHODS: Noninterventional, observational, multicenter study in Norway....

Descripción completa

Detalles Bibliográficos
Autores principales: Abedini, Sadollah, Gøransson, Lasse, Cockburn, Elinor, Kilany, Suzanne, Holdaas, Hallvard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811267/
https://www.ncbi.nlm.nih.gov/pubmed/29464199
http://dx.doi.org/10.1097/TXD.0000000000000755
_version_ 1783299840587857920
author Abedini, Sadollah
Gøransson, Lasse
Cockburn, Elinor
Kilany, Suzanne
Holdaas, Hallvard
author_facet Abedini, Sadollah
Gøransson, Lasse
Cockburn, Elinor
Kilany, Suzanne
Holdaas, Hallvard
author_sort Abedini, Sadollah
collection PubMed
description BACKGROUND: This study investigated medication adherence in kidney transplant patients (KTPs) converted from immediate-release tacrolimus (IR-T) to prolonged-release tacrolimus (PR-T)-based immunosuppression in routine practice. METHODS: Noninterventional, observational, multicenter study in Norway. Included adult KTPs with stable graft function, converted from IR-T (baseline) to PR-T (1 mg:1 mg) in routine practice. Data were collected at baseline, and months 1, 3, 6, and 12 postconversion. Primary endpoint: adherence using the Basel Assessment of Adherence to Immunosuppressive Medication Scale. Secondary assessments: tacrolimus dose and trough levels (target, 3-7 ng/mL), clinical laboratory parameters (eg, estimated glomerular filtration rate [Modified Diet in Renal Disease]), and adverse events. RESULTS: Ninety-one KTPs (mean ± SD age 47.7 ± 14.3 years) were analyzed. Mean ± SD change in PR-T dose from baseline (4.4 ± 2.4 mg/d) to month 12 was −0.1 ± 0.9 mg/d; mean tacrolimus trough levels remained within target. Overall medication adherence increased from 45.6% at baseline to 58.1% at month 1, but was similar to baseline thereafter; taking and timing adherence followed a similar pattern. Odds ratio (OR) for adherence at month 1 (but not at other time points) was greater versus baseline for overall (OR, 1.71; P = 0.0205), taking (OR, 3.38; P = 0.0004), and timing (OR, 1.77, P = 0.0252) dimensions. Mean ± SD Basel Assessment of Adherence to Immunosuppressive Medication Scale visual analogue scale score at baseline was 96.4 ± 5.5%, and increased postconversion. Estimated glomerular filtration rate remained stable (month 12, 61.6 ± 17.7 mL/min per 1.73 m(2)), as did other laboratory parameters. Two (2.2%) patients had adverse events considered probably/possibly treatment-related. CONCLUSIONS: There was disparity between high, patient-perceived and low, actual adherence. Converting stable KTPs from IR-T to PR-T in routine practice did not impact long-term adherence to immunosuppression; renal function remained stable.
format Online
Article
Text
id pubmed-5811267
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-58112672018-02-20 Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study Abedini, Sadollah Gøransson, Lasse Cockburn, Elinor Kilany, Suzanne Holdaas, Hallvard Transplant Direct Kidney Transplantation BACKGROUND: This study investigated medication adherence in kidney transplant patients (KTPs) converted from immediate-release tacrolimus (IR-T) to prolonged-release tacrolimus (PR-T)-based immunosuppression in routine practice. METHODS: Noninterventional, observational, multicenter study in Norway. Included adult KTPs with stable graft function, converted from IR-T (baseline) to PR-T (1 mg:1 mg) in routine practice. Data were collected at baseline, and months 1, 3, 6, and 12 postconversion. Primary endpoint: adherence using the Basel Assessment of Adherence to Immunosuppressive Medication Scale. Secondary assessments: tacrolimus dose and trough levels (target, 3-7 ng/mL), clinical laboratory parameters (eg, estimated glomerular filtration rate [Modified Diet in Renal Disease]), and adverse events. RESULTS: Ninety-one KTPs (mean ± SD age 47.7 ± 14.3 years) were analyzed. Mean ± SD change in PR-T dose from baseline (4.4 ± 2.4 mg/d) to month 12 was −0.1 ± 0.9 mg/d; mean tacrolimus trough levels remained within target. Overall medication adherence increased from 45.6% at baseline to 58.1% at month 1, but was similar to baseline thereafter; taking and timing adherence followed a similar pattern. Odds ratio (OR) for adherence at month 1 (but not at other time points) was greater versus baseline for overall (OR, 1.71; P = 0.0205), taking (OR, 3.38; P = 0.0004), and timing (OR, 1.77, P = 0.0252) dimensions. Mean ± SD Basel Assessment of Adherence to Immunosuppressive Medication Scale visual analogue scale score at baseline was 96.4 ± 5.5%, and increased postconversion. Estimated glomerular filtration rate remained stable (month 12, 61.6 ± 17.7 mL/min per 1.73 m(2)), as did other laboratory parameters. Two (2.2%) patients had adverse events considered probably/possibly treatment-related. CONCLUSIONS: There was disparity between high, patient-perceived and low, actual adherence. Converting stable KTPs from IR-T to PR-T in routine practice did not impact long-term adherence to immunosuppression; renal function remained stable. Lippincott Williams & Wilkins 2018-01-03 /pmc/articles/PMC5811267/ /pubmed/29464199 http://dx.doi.org/10.1097/TXD.0000000000000755 Text en Copyright © 2018 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Kidney Transplantation
Abedini, Sadollah
Gøransson, Lasse
Cockburn, Elinor
Kilany, Suzanne
Holdaas, Hallvard
Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study
title Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study
title_full Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study
title_fullStr Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study
title_full_unstemmed Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study
title_short Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study
title_sort immunosuppression adherence in stable kidney transplant patients converted from immediate- to prolonged-release tacrolimus in clinical practice: a norwegian study
topic Kidney Transplantation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811267/
https://www.ncbi.nlm.nih.gov/pubmed/29464199
http://dx.doi.org/10.1097/TXD.0000000000000755
work_keys_str_mv AT abedinisadollah immunosuppressionadherenceinstablekidneytransplantpatientsconvertedfromimmediatetoprolongedreleasetacrolimusinclinicalpracticeanorwegianstudy
AT gøranssonlasse immunosuppressionadherenceinstablekidneytransplantpatientsconvertedfromimmediatetoprolongedreleasetacrolimusinclinicalpracticeanorwegianstudy
AT cockburnelinor immunosuppressionadherenceinstablekidneytransplantpatientsconvertedfromimmediatetoprolongedreleasetacrolimusinclinicalpracticeanorwegianstudy
AT kilanysuzanne immunosuppressionadherenceinstablekidneytransplantpatientsconvertedfromimmediatetoprolongedreleasetacrolimusinclinicalpracticeanorwegianstudy
AT holdaashallvard immunosuppressionadherenceinstablekidneytransplantpatientsconvertedfromimmediatetoprolongedreleasetacrolimusinclinicalpracticeanorwegianstudy